The GuardOne clinical trial: A first-in-human, open-label, multinational phase 1/2 study of AVR-RD-02 ex vivo lentiviral vector, autologous gene therapy for Gaucher disease
Leslie K. Jacobsen(Johns Hopkins University), Chris Mason(Oak Ridge National Laboratory), Julie A. Kerner, Josie Yang, Azadeh Golipour(ProterixBio (United States)), Rachel Ciotti, Richard W. Pfeifer(ProterixBio (United States))
Cited by 1
Related Papers
A Brief Definition of Regenerative Medicine
|Regenerative Medicine|2007|795
BTRFS
|ACM Transactions on Storage|2013|381
Lancet Commission: Stem cells and regenerative medicine
|The Lancet|2017|276
Cell Therapy Industry: Billion Dollar Global Business with Unlimited Potential
|Regenerative Medicine|2011|144
Peak Serum: Implications of Serum Supply for Cell Therapy Manufacturing
|Regenerative Medicine|2011|144